Clinical trial
An Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy With or Without Concomitant Dopaminergic Medications
NCT05116813 is registered in ClinicalTrials.gov with Addex Pharma S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy With or Without Concomitant Dopaminergic Medications
- Lead sponsor
- Addex Pharma S.A.
- Phase
- Phase 2/3
- Overall status
- Terminated
- Start date
- October 25, 2021
- Completion date
- August 15, 2022
- Enrollment
- 17 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.